07 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: CSL Biotherapies, the US subsidiary of Australia-based CSL, has begun the shipment of its seasonal influenza vaccine for the 2013-14 season.
CSL Biotherapies will ship approximately 11 million doses of the seasonal flu vaccine to the US for the upcoming season. Shipment will comprise multi-dose and pre-filled syringe presentations.
Dr Marie Mazur, head, Worldwide Commercial Operations, Influenza, CSL Biotherapies, said that, "Given the magnitude of influenza burden in the US and the unpredictability of seasonal outbreaks, timely delivery of flu vaccines is more critical now than ever before. CSL Biotherapies is committed to addressing this public health need by consistently delivering its influenza vaccine early to the healthcare providers in the US."